INBX · Inhibrx Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Inhibrx, Inc. | ▼ Sell | Other | 1,157,926 Shares held | 5/29/2024 | View profile |
| Mark Lappe Chief Executive Officer | ▲ Buy | Open Market | 740,548 Shares held | 9/28/2026 | View profile |
| Jon Faiz Kayyem Director | ▲ Buy | Open Market | 434,360 Shares held | 9/23/2026 | View profile |
| Douglas Forsyth Director | ▲ Buy | Open Market | 227,064 Shares held | 9/8/2026 | View profile |
| VIKING GLOBAL INVESTORS LP 10% Owner | ▼ Sell | Open Market | 102,864 Shares held | 10/7/2025 | View profile |
| Brendan P. Eckelman Chief Scientific Officer | ▲ Buy | Grant | 40,000 Shares held | 5/29/2024 | View profile |
| Kristiina Vuori, MD Director | ▲ Buy | Open Market | 20,443 Shares held | 10/3/2024 | View profile |
| Kimberly Manhard Director | ▼ Sell | Open Market | 7,500 Shares held | 9/15/2026 | View profile |
Transaction History
| Mark Lappe | ▲ Buy | Open Market | 1,500 | $148K | 9/28/2026 |
| Mark Lappe | ▲ Buy | Open Market | 3,000 | $305K | 9/28/2026 |
| Mark Lappe | ▲ Buy | Open Market | 3,324 | $329K | 9/25/2026 |
| Mark Lappe | ▲ Buy | Open Market | 2,176 | $217K | 9/25/2026 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 5,000 | $500K | 9/23/2026 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 5,000 | $500K | 9/16/2026 |
| Kimberly Manhard | ▼ Sell | Open Market | 500 | $53K | 9/15/2026 |
| Kimberly Manhard | ▼ Sell | Open Market | 500 | $55K | 9/14/2026 |
| Kimberly Manhard | ▼ Sell | Open Market | 500 | $56K | 9/11/2026 |
| Kimberly Manhard | ▼ Sell | Open Market | 500 | $58K | 9/9/2026 |
| Kimberly Manhard | ▼ Sell | Open Market | 500 | $58K | 9/8/2026 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 5,000 | $568K | 9/8/2026 |
| Douglas Forsyth | ▲ Buy | Open Market | 2,500 | $287K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 5,895 | $585K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 6,605 | $665K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 1,100 | $118K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 500 | $54K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 1,219 | $136K | 9/8/2026 |
| Mark Lappe | ▲ Buy | Open Market | 9,681 | $1.1M | 9/8/2026 |
| VIKING GLOBAL INVESTORS LP | ▼ Sell | Open Market | 308,643 | $10.0M | 10/7/2025 |
| VIKING GLOBAL INVESTORS LP | ▼ Sell | Open Market | 16,315 | $526K | 10/7/2025 |
| VIKING GLOBAL INVESTORS LP | ▼ Sell | Open Market | 25,042 | $808K | 10/7/2025 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 90,000 | $0 | 3/27/2025 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 500,000 | $0 | 12/16/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 250,000 | $0 | 12/16/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 250,000 | $0 | 12/16/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 52,000 | $0 | 12/6/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 18,750 | $266K | 11/20/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 18,750 | $266K | 11/20/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 34,843 | $496K | 11/19/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 34,843 | $496K | 11/19/2024 |
| Kristiina Vuori, MD | ▲ Buy | Open Market | 6,667 | $100K | 10/3/2024 |
| Mark Lappe | ▲ Buy | Open Market | 13,037 | $223K | 9/16/2024 |
| Mark Lappe | ▲ Buy | Open Market | 26,963 | $406K | 9/12/2024 |
| Kristiina Vuori, MD | ▲ Buy | Open Market | 6,457 | $97K | 9/11/2024 |
| Kristiina Vuori, MD | ▲ Buy | Open Market | 179 | $3K | 9/10/2024 |
| Mark Lappe | ▲ Buy | Open Market | 8,500 | $129K | 9/10/2024 |
| Mark Lappe | ▲ Buy | Open Market | 9,500 | $144K | 9/9/2024 |
| Mark Lappe | ▲ Buy | Open Market | 26,000 | $398K | 9/6/2024 |
| Mark Lappe | ▲ Buy | Open Market | 4,712 | $77K | 9/3/2024 |
| Mark Lappe | ▲ Buy | Open Market | 15,288 | $239K | 9/3/2024 |
| Mark Lappe | ▲ Buy | Open Market | 10,000 | $140K | 8/30/2024 |
| Mark Lappe | ▲ Buy | Open Market | 10,000 | $140K | 8/29/2024 |
| Kristiina Vuori, MD | ▲ Buy | Open Market | 7,140 | $100K | 8/29/2024 |
| Kimberly Manhard | ▲ Buy | Open Market | 10,000 | $140K | 8/28/2024 |
| Douglas Forsyth | ▲ Buy | Open Market | 59,812 | $842K | 8/23/2024 |
| Douglas Forsyth | ▲ Buy | Open Market | 15,188 | $196K | 8/22/2024 |
| Mark Lappe | ▲ Buy | Open Market | 12,945 | $167K | 8/21/2024 |
| Mark Lappe | ▲ Buy | Open Market | 27,055 | $351K | 8/20/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 89,050 | $0 | 6/24/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 10,000 | $0 | 6/24/2024 |
| Jon Faiz Kayyem | ▼ Sell | Gift | 10,000 | $0 | 6/24/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 49,284 | $849K | 6/5/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 8,265 | $148K | 6/5/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 65,337 | $1.1M | 6/4/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 23,726 | $433K | 6/4/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 46,792 | $777K | 6/3/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 80,738 | $1.4M | 6/3/2024 |
| Jon Faiz Kayyem | ▲ Buy | Open Market | 70,193 | $1.1M | 5/31/2024 |
| Jon Faiz Kayyem | ▲ Buy | Grant | 6,250 | — | 5/29/2024 |
| Jon Faiz Kayyem | ▲ Buy | Grant | 6,250 | — | 5/29/2024 |
| Jon Faiz Kayyem | ▲ Buy | Grant | 806,075 | — | 5/29/2024 |
| Inhibrx, Inc. | ▼ Sell | Other | 13,316,140 | — | 5/29/2024 |
| Mark Lappe | ▲ Buy | Grant | 621,548 | — | 5/29/2024 |
| Mark Lappe | ▲ Buy | Grant | 125,000 | — | 5/29/2024 |
| Mark Lappe | ▲ Buy | Grant | 14,865 | — | 5/29/2024 |
| Douglas Forsyth | ▲ Buy | Grant | 149,564 | — | 5/29/2024 |
| Brendan P. Eckelman | ▲ Buy | Grant | 433,888 | — | 5/29/2024 |
| Brendan P. Eckelman | ▲ Buy | Grant | 40,000 | — | 5/29/2024 |
| Brendan P. Eckelman | ▲ Buy | Grant | 40,000 | — | 5/29/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.